Biosimilar medicines have been on the European market for more than 15 years and it has been precisely the experience of clinical practice that has shown that in terms of efficacy, safety and immunogenicity they are comparable to their reference products and, therefore, they are interchangeable.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
